Results 121 to 130 of about 4,315,874 (223)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome

Clinics, 2013
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.
Bruno Deltreggia Benites, Carolina Silva Costa Lima, Irene Lorand-Metze, Marcia Torresan Delamain, Gislaine Borba Oliveira, Daiane de Almeida, Carmino Antonio de Souza, Jose Vassallo, Katia Borgia Barbosa Pagnano   +8 more
doaj  

Recent developments in myelofibrosis

, 2012
Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USAAbstract: The myeloproliferative neoplasm of myelofibrosis (MF) is clinically constituted by individuals both with primary MF, as well as ...
Tibes R, Mesa RA, Bogenberger JM
core  

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis

, 2018
Purpose of Review: The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment ...
Barbara Mora, Daniela Barraco, Mora, Barbara, Margherita Maffioli, Barraco, Daniela, Francesco Passamonti, Maffioli, Margherita, Passamonti, Francesco   +7 more
core   +1 more source

Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis

, 2017
Primary myelofibrosis is characterized by bone marrow fibrosis, splenomegaly and presence of JAK-2 V617F mutation in more than 90% of patients. Ruxolitinib is a Janus kinase inhibitor used for the treatment of primary myelofibrosis. We describe herein a
Constantin A Dasanu, Henry Tsai, Michael Del Rosario   +2 more
core   +1 more source

Reticulosarcomatosis in primary myelofibrosis [PDF]

Cancer, 1968
openaire   +2 more sources

From primary myelofibrosis to chronic myeloid leukemia, BCR::ABL1+ B‐Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolution

eJHaem
The simultaneous detection of BCR::ABL1 and JAK2 V617F was rarely reported and their clonal relationship and dynamic clonal shift were not characterized. Here, we described a unique case with the initial presentation as JAK2 V617F+ primary myelofibrosis,
Devin Wang, Wataru Kamata, Fengxi Ye, M. James You   +3 more
doaj   +1 more source

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study

Therapeutic Advances in Hematology
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease.
Han Xu, Yujie Xu, Mengying Wang, Chunxia Mao, Junxia Huang, Tianlan Li, Yan Gao, Shanshan Liu, Jingjing Zhou, Yi Zhang, Xianqi Feng   +10 more
doaj   +1 more source

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia

, 2018
Monocytosis can develop during disease course in primary myelofibrosis simulating that seen in chronic myelomonocytic leukemia, and should not lead to disease reclassification.
Geyer, Julia T, Watts, Justin M, Jennifer Chapman, Ronan T Swords, Connor, Scot T, Vega, Francisco, Julia T Geyer, Yao-Shan Fan, Justin M Watts, Attilio Orazi, Adrienne Moul, Fan, Yao-Shan, Carmen Casas, Moul, Adrienne, Swords, Ronan T, Francisco Vega, Chapman, Jennifer, Orazi, Attilio, Khanlari, Mahsa, Scot T Connor, Mahsa Khanlari, Casas, Carmen   +21 more
core   +1 more source

Bone Marrow Reticulin Content In Acute Leukemia

مجلة كلية الطب, 2006
Background: Increase in marrow reticulin has long been recognized in primary myelofibrosis, but little was known about the reticulin structure of leukemic marrows, there has been a tendency to accept an increase in marrow reticulin as evidence of ...
Eman Sadiq Jalal
doaj  

Integrating Next Generation sequencing into the risk assessment of primary myelofibrosis. [PDF]

Hematol Transfus Cell Ther
Reis-Vieira R, da Costa JB, Coutinho D, Arcuri LJ, D'Andrea M, Robledo ML, Daumas AH, Solza C, Boroni M, Zalcberg I, Monte-Mór BDCR.   +10 more
europepmc   +1 more source